Oxford BioTherapeutics Ltd. (OBT)

http://www.oxbt.co.uk

Oxford BioTherapeutics, a clinical stage biotechnology company, is developing a range of innovative antibody based therapeutics, including antibody-drug conjugates (ADCs), for the treatment of cancer. The company’s ADCs are based on its proprietary OGAP® targeting platform, and incorporate novel antibody and cancer toxin technologies accessed from leading companies in the field. Oxford BioTherapeutics’ network of collaborations provides a unique range of complementary ADC technologies, allowing the company to select the optimal combination for each target identified by its OGAP® system. OGAP® incorporates one of the world’s largest proprietary cell-membrane focused proteomic databases, with data on over 5,000 cancer membrane proteins providing unique, highly-qualified oncology targets that are selected for optimal ADC activity. *

	Start	2008-12-01 renamed
	Predecessor	Oxford Genome Sciences (UK) Ltd. (OGeS)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	Oxford Genome Anatomy Project (OGAP) database
	Person	Rohlff, Christian (Oxford BioTherapeutics 201506 CEO before Oxford Genome Sciences CEO)
	Person 2	Wilson, Keith (Oxford BioTherapeutics 201506 CSO)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	94a Milton Park
	City	OX14 4RY Abingdon, Oxfordshire
	Tel	+44-1235-861770
		Address record changed: 2018-07-24

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Invenra, Inc.. (6/25/15). "Press Release: Invenra and Oxford BioTherapeutics Enter Collaboration to Discover Novel Therapeutic Antibodies Targeting Cancer". Madison, WI & Oxford.

		Record changed: 2019-06-09